PeptideStack
5.2kquestions
20kanswers
220users

clinical-trials

Page 18 of 32 · 745 questions tagged clinical-trials.

745 questions · sorted by votes · page 18 of 32

18 votes 5 answers13k views
Is ESSENCE a fair comparison of semaglutide against its comparator arm?

Stated plainly: ESSENCE · semaglutide. I would rather be corrected now than propagate something wrong. I am specifically not interested in a testimonial; I am…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
tirzepatide
tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

370 questions
asked by lukas_sedlacek 16k · 13 months ago
18 votes 5 answers13k views
Is orforglipron comparable to a peptide agonist on any axis?

I would like to know how much of this is established and how much is a reasonable story. I want to know what the trade-off actually is rather than which option is…

orforglipron
orforglipron

A non-peptide, orally bioavailable small-molecule GLP-1 receptor agonist studied in the ATTAIN programme. It is not a peptide, which changes…

219 questions
oral-glp1
oral-glp1

Oral routes for GLP-1 receptor agonism: peptide formulations rescued by absorption enhancers such as SNAC, and true small molecules that need no…

219 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
asked by Dr_Lena_Ostrowska 38k · 10 months ago
18 votes 5 answers12k views
What does the mechanism of retatrutide predict that TRIUMPH-1 did not test?

The case in front of me: retatrutide · TRIUMPH-1. This is one of those things that everyone repeats and nobody derives. This matters practically, not just…

glp1-mechanism
glp1-mechanism

Receptor-level pharmacology: GLP-1R as a class B GPCR, cAMP and PKA signalling, biased agonism, internalisation and resensitisation, and the…

132 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
gip-receptor
gip-receptor

GIP receptor pharmacology, and the still-unsettled question of whether agonism or antagonism at GIPR is the metabolically useful direction.…

34 questions
retatrutide
retatrutide

An investigational GLP-1, GIP and glucagon receptor tri-agonist, studied in the TRIUMPH programme. Not approved anywhere. Use this tag for…

251 questions
asked by birk_nordahl 16k · 20 months ago
18 votes 2 answers11k views
What does FLOW tell me about reflux at the 1 mg dose?

The case in front of me: FLOW · reflux · 1 mg. The figures are clear enough; the question is what they mean and what they do not. I can supply the numbers if the…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
gi-side-effects
gi-side-effects

The gastrointestinal cluster as a whole - nausea, vomiting, diarrhoea, constipation, reflux, early satiety - with trial incidence rates, dropout…

162 questions
titration
titration

Stepwise dose increases over weeks, why the label schedules exist at all, and what tolerability-driven deviation from a schedule looks like in…

456 questions
asked by wren_calloway 23k · 11 months ago
18 votes1 answer10k views
What did the placebo arm of SURMOUNT-4 report for nausea?

Numbers first: SURMOUNT-4 · nausea. I can parse the result. I am less sure what it licenses me to conclude. I have deliberately not looked at anyone else’s…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
nausea
nausea

The dominant tolerability signal in every trial of the class: incidence, timing relative to a dose step, duration, and the distinction between…

55 questions
asked by RP_C18 105k · 8 months ago
18 votes0 answers10k views
Do the cardiovascular benefits depend on the weight loss?

This is a question about interpretation, not about whether to act — I will take action questions elsewhere. I want to know whether this is a real physical effect or…

cardiovascular
cardiovascular

Cardiovascular outcomes: the SELECT major-adverse-event result, SOUL, SUSTAIN 6 and REWIND, how to convert a hazard ratio into an absolute risk…

68 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
lipids
lipids

Lipid response on treatment: triglycerides, LDL-C, non-HDL-C, ApoB and Lp(a), which of them move with weight loss, and why a fasting panel drawn…

139 questions
asked by Dr_Wren_Halliday 19k · 11 months ago
18 votes0 answers10k views
Is SURMOUNT-1 a fair comparison of a GLP-1 receptor agonist against its comparator arm?

Setup, so nobody has to ask: SURMOUNT-1 · a GLP-1 receptor agonist. This has the shape of a fact but I cannot find its origin. What I found instead were three…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
tirzepatide
tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

370 questions
asked by cake_collapsed 14k · 16 months ago
18 votes5 answers10k views
What is the reported incidence of nausea on oral semaglutide in SOUL?

The particulars: nausea · oral semaglutide · SOUL. The figures are clear enough; the question is what they mean and what they do not. I can supply the numbers if the…

nausea
nausea

The dominant tolerability signal in every trial of the class: incidence, timing relative to a dose step, duration, and the distinction between…

55 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
oral-glp1
oral-glp1

Oral routes for GLP-1 receptor agonism: peptide formulations rescued by absorption enhancers such as SNAC, and true small molecules that need no…

219 questions
asked by ivo_paunovic 16k · 15 months ago
18 votes2 answers8.4k views
What does PIONEER-4 tell me about hair thinning at the 25 mg dose?

Numbers first: PIONEER-4 · hair thinning · 25 mg. I can parse the result. I am less sure what it licenses me to conclude. I have deliberately not looked at anyone…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
hair-loss
hair-loss

Telogen effluvium following rapid weight loss versus a drug-attributable effect: the timing signature that distinguishes them, protein and…

50 questions
titration
titration

Stepwise dose increases over weeks, why the label schedules exist at all, and what tolerability-driven deviation from a schedule looks like in…

456 questions
asked by pip_okonjo 13k · 14 months ago
18 votes 5 answers8.4k views
What does STEP 8 report at the 2.4 mg dose level?

Concretely: STEP 8 · 2.4 mg. The figures are clear enough; the question is what they mean and what they do not. I can supply the numbers if the specifics change the…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
dosing-math
dosing-math

The arithmetic itself: milligrams to millilitres to insulin units, concentration after reconstitution, dose per draw, and vial-days per vial. Show…

764 questions
titration
titration

Stepwise dose increases over weeks, why the label schedules exist at all, and what tolerability-driven deviation from a schedule looks like in…

456 questions
asked by Dr_Ilse_Vandenberg 113k · 4 months ago
18 votes5 answers8.2k views
What does STEP 2 tell me about reflux at the 2 mg dose?

The case in front of me: STEP 2 · reflux · 2 mg. The figures are clear enough; the question is what they mean and what they do not. I can supply the numbers if the…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
gi-side-effects
gi-side-effects

The gastrointestinal cluster as a whole - nausea, vomiting, diarrhoea, constipation, reflux, early satiety - with trial incidence rates, dropout…

162 questions
titration
titration

Stepwise dose increases over weeks, why the label schedules exist at all, and what tolerability-driven deviation from a schedule looks like in…

456 questions
asked by tess_amankwah 22k · 15 months ago
18 votes5 answers7.8k views
What is the reported incidence of vomiting on retatrutide in TRIUMPH-1?

What I have: vomiting · retatrutide · TRIUMPH-1. This is presented as though it settles something, and I am not convinced it does. I have two documents that appear to…

vomiting
vomiting

Emesis as a reported adverse event: trial incidence, its relationship to dose escalation rate, dehydration risk, and when it stops being a…

57 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
retatrutide
retatrutide

An investigational GLP-1, GIP and glucagon receptor tri-agonist, studied in the TRIUMPH programme. Not approved anywhere. Use this tag for…

251 questions
asked by cake_intact 17k · 10 months ago
18 votes 5 answers5.5k views
What did the placebo arm of SURMOUNT-2 report for injection-site erythema?

What I am working with: SURMOUNT-2 · injection-site erythema. I would like help reading this properly rather than being told what conclusion to reach. I have the full…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
injection-site-reaction
injection-site-reaction

Local reactions: erythema, induration, pruritus and nodules. Their relationship to injection depth, diluent composition, benzyl alcohol…

49 questions
asked by Dr_Tomas_Kral 53k · 3 months ago
18 votes4 answers5k views
Is SURPASS-2 a fair comparison of tirzepatide against its comparator arm?

Details up front: SURPASS-2 · tirzepatide. I am asking for verification rather than opinion, ideally with something I can read myself. It is possible the evidence…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
tirzepatide
tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

370 questions
asked by ilaria_bertone 33k · 3 months ago
18 votes5 answers3.4k views
What does SURMOUNT-OSA actually establish about a GLP-1 receptor agonist?

What I am working with: SURMOUNT-OSA · a GLP-1 receptor agonist. I would like help reading this properly rather than being told what conclusion to reach. I have the…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
cardiovascular
cardiovascular

Cardiovascular outcomes: the SELECT major-adverse-event result, SOUL, SUSTAIN 6 and REWIND, how to convert a hazard ratio into an absolute risk…

68 questions
asked by area_percent 9.9k · 2 months ago
18 votes 3 answers3k views
What did the placebo arm of REDEFINE-1 report for hair thinning?

Numbers first: REDEFINE-1 · hair thinning. This is presented as though it settles something, and I am not convinced it does. I have two documents that appear to…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
hair-loss
hair-loss

Telogen effluvium following rapid weight loss versus a drug-attributable effect: the timing signature that distinguishes them, protein and…

50 questions
asked by Dr_Signe_Baldursdottir 29k · 2 months ago
17 votes 5 answers41k views
How comparable are cagrilintide and retatrutide on the evidence available?

What I am working with: cagrilintide · retatrutide. I want to know what the trade-off actually is rather than which option is fashionable. I would rather have a…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
tirzepatide
tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

370 questions
amylin
amylin

Amylin and its analogues, most prominently cagrilintide, as a satiety mechanism orthogonal to incretin signalling. Includes the pharmacology of…

237 questions
retatrutide
retatrutide

An investigational GLP-1, GIP and glucagon receptor tri-agonist, studied in the TRIUMPH programme. Not approved anywhere. Use this tag for…

251 questions
asked by e_dziedzic 51k · 2.1 years ago
17 votes 5 answers40k views
What did the placebo arm of SOUL report for constipation?

What I have: SOUL · constipation. I want to understand what this actually establishes, as opposed to what it is being used to imply. My concern is that I am being…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
constipation
constipation

Slowed transit as a consequence of delayed gastric emptying and reduced intake: incidence figures, fibre and hydration evidence, and why it often…

55 questions
asked by second_lot 9.4k · 23 months ago
17 votes 5 answers30k views
What does TRIUMPH-3 tell me about headache at the 12 mg dose?

What I have: TRIUMPH-3 · headache · 12 mg. I can parse the result. I am less sure what it licenses me to conclude. I have deliberately not looked at anyone else’s…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
titration
titration

Stepwise dose increases over weeks, why the label schedules exist at all, and what tolerability-driven deviation from a schedule looks like in…

456 questions
asked by n_takahashi 29k · 23 months ago
17 votes 5 answers28k views
Is there any published stability data for cagrilintide at 37 °C?

What I have: cagrilintide · 37 °C. I would rather be corrected now than propagate something wrong. I am specifically not interested in a testimonial; I am interested…

peptide-stability
peptide-stability

The chemistry of peptide degradation: deamidation, oxidation, hydrolysis, aggregation and fibrillation, and how temperature, pH, ionic strength,…

908 questions
storage
storage

Storage conditions and their evidence base: minus twenty degrees for powder, refrigerated for solution, protection from light, and what the…

701 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
amylin
amylin

Amylin and its analogues, most prominently cagrilintide, as a satiety mechanism orthogonal to incretin signalling. Includes the pharmacology of…

237 questions
asked by elke_brunner 17k · 2.3 years ago
17 votes4 answers23k views
How comparable are a GLP-1 receptor agonist and mazdutide on the evidence available?

Numbers first: a GLP-1 receptor agonist · mazdutide. I want to know what the trade-off actually is rather than which option is fashionable. I would rather have a…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
tirzepatide
tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

370 questions
mazdutide
mazdutide

A GLP-1 and glucagon receptor dual agonist developed primarily in China, with a distinct dose range and a fast-moving publication record.…

237 questions
asked by sunniva_dahl 22k · 2.2 years ago
17 votes 5 answers22k views
What is the reported incidence of fatigue on retatrutide in TRIUMPH-1?

Details up front: fatigue · retatrutide · TRIUMPH-1. I can parse the result. I am less sure what it licenses me to conclude. I have deliberately not looked at anyone…

fatigue
fatigue

Tiredness on treatment: how much is energy deficit, how much is dehydration or electrolyte drift, how much is genuinely drug-attributable, and…

78 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
retatrutide
retatrutide

An investigational GLP-1, GIP and glucagon receptor tri-agonist, studied in the TRIUMPH programme. Not approved anywhere. Use this tag for…

251 questions
asked by tobias_reint 20k · 23 months ago
17 votes 5 answers22k views
What does TRIUMPH-1 tell me about reflux at the 8 mg dose?

Setup, so nobody has to ask: TRIUMPH-1 · reflux · 8 mg. I have read the primary source rather than the summary, which has left me with more questions. I understand…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
gi-side-effects
gi-side-effects

The gastrointestinal cluster as a whole - nausea, vomiting, diarrhoea, constipation, reflux, early satiety - with trial incidence rates, dropout…

162 questions
titration
titration

Stepwise dose increases over weeks, why the label schedules exist at all, and what tolerability-driven deviation from a schedule looks like in…

456 questions
asked by nine_point_nine 60k · 12 months ago
17 votes5 answers20k views
What did the placebo arm of FLOW report for hair thinning?

Stated plainly: FLOW · hair thinning. I have the document in front of me and I can read the numbers. What I cannot do is interpret them. I am reasonably comfortable…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
hair-loss
hair-loss

Telogen effluvium following rapid weight loss versus a drug-attributable effect: the timing signature that distinguishes them, protein and…

50 questions
asked by birk_nordahl 16k · 20 months ago